{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:40:39Z","timestamp":1792424439230,"version":"4.5.0"},"reference-count":5,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"DOI":"10.1001\/jama.2026.17239","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:00:17Z","timestamp":1792422017000},"source":"Crossref","is-referenced-by-count":0,"title":["Illicit Injectable Peptides"],"prefix":"10.1001","author":[{"given":"Carolina Castro Porto Silva","family":"Janovsky","sequence":"first","affiliation":[{"name":"Endocrinology Unit, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"issue":"3","key":"jle260161r1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jama.2026.10690","article-title":"Illicit injectable peptides and regulatory gaps.","volume":"336","author":"Piatkowski","year":"2026","journal-title":"JAMA"},{"issue":"12","key":"jle260161r3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s12178-025-09990-7","article-title":"Regeneration or risk? a narrative review of BPC-157 for musculoskeletal healing.","volume":"18","author":"McGuire","year":"2025","journal-title":"Curr Rev Musculoskelet Med"},{"key":"jle260161r2","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Peptides that promise miracles are not registered with Anvisa. In Portuguese. Published July 2, 2026. Accessed July 24, 2026. https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2026\/checamos-peptideos-que-prometem-milagres-nao-estao-registrados-na-anvisa"},{"key":"jle260161r4","unstructured":"US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. April 22, 2026. Accessed July 24, 2026. https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"key":"jle260161r5","unstructured":"Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade. Recommendation report No. 1033: semaglutide for the treatment of patients aged 45 years or older with class II or III obesity, without diabetes, and with established cardiovascular disease. In Portuguese. August 2025. Accessed July 24, 2026. https:\/\/www.gov.br\/conitec\/pt-br\/midias\/relatorios\/2025\/relatorio-de-recomendacao-com-decisao-final-no-1033-semaglutida\/@@display-file\/file"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2855488\/jama_janovsky_2026_le_260161_1791838648.04771.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:00:19Z","timestamp":1792422019000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2855488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":5,"URL":"https:\/\/doi.org\/10.1001\/jama.2026.17239","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,19]]}}}